Long-term Follow-up of Study Participants Who Received an Allogeneic Chimeric Antigen Receptor T-Cell Product in an Imugene Ltd. Clinical Study

Condition(s) studied

Study summary

The goal of this observational study is to collect information on the long-term safety of study participants who received an Allogeneic Chimeric Antigen Receptor (CAR) T-Cell Product in an Imugene Clinical Study. The main questions it aims to answer are:

* What are the frequency, severity, duration, and outcome of clinically significant Clinical Events of Interest (CEI)?
* What is the duration of response and overall survival time after taking an allogeneic CAR T-Cell product on an Imugene clinical study?

Participants will have a yearly visit either face to face or remotely for up to 15 years to check for CEI.

Eligibility

Primary outcome measure(s)

• Frequency of Clinically Significant Clinical Events of Interest (CEI) — Up to 15 years
• Severity of Clinically Significant CEI — Up to 15 years
• Duration of Clinically Significant CEI — Up to 15 years
• Outcome of Clinically Significant CEI — Up to 15 years

Trial sites (1)

More Imugene Limited trials in the USA